Storys aus Germany

16.11.2016 – 18:14
Grünenthal Group
Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease
Aachen, Germany / Pittsburgh, PA, USA (ots) - - The acquisition supports Grünenthal's commercial and R&D strategy to drive innovation in pain. - Thar Pharmaceutical's lead compound, T121, complements Grünenthal's existing development pipeline and the goal of delivering innovative and effective treatments to ...
mehr
16.11.2016 – 13:00
Adient Ltd. & Co. KG
Adient honors leading suppliers for commitment to excellence in 2016
Plymouth, Michigan and Burscheid, Germany (ots) - Adient, the world's largest global automotive seating supplier, today recognized 51 suppliers for their leadership and superior performance. The suppliers were honored during the company's annual Supplier Performance Awards ceremony held in Detroit. "We congratulate all of our outstanding suppliers for their commitment ...
mehr
31.10.2016 – 08:02
Merck and Pfizer
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma - The Marketing Authorization Application is based on Phase II data from the ...
mehr
28.10.2016 – 09:16
Astellas Pharma EMEA
Astellas to Acquire Ganymed Pharmaceuticals
Tokyo and Mainz, Germany (ots/PRNewswire) - - Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, "Ganymed"), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas ...
mehr
28.10.2016 – 07:01
GfK SE
Eyesight and Memory Loss are Leading Concerns Around Aging
Nuremberg, Germany (ots/PRNewswire) - Internationally, the top five physical conditions that people worry most about having, either now or as they age, are eyesight getting poorer, not being as mentally alert, lacking energy, having trouble taking care of themselves physically, and being unable to walk or drive. These are the findings from a GfK survey (http://www.gfk.com/global-studies/global-study-overview/) of the ...
mehr
10.10.2016 – 08:15
Merck Healthcare Germany
Merck KGaA, Darmstadt, Germany, Announces Recipients of Third Annual EUR1 Million 'Grant for Oncology Innovation' Award
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Grant established by Merck KGaA, Darmstadt, Germany, recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck KGaA, ...
mehr

10.10.2016 – 08:10
Merck Healthcare Germany
Merck Announces Recipients of Third Annual EUR1 Million 'Grant for Oncology Innovation' Award
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or UK-based media - Grant established by Merck recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck, a leading science and technology company, today announced the recipients of ...
mehr
29.09.2016 – 10:02
GfK SE
A Third of People Track Their Health or Fitness. Who Are They and Why Are They Doing it?
Nuremberg, Germany (ots/PRNewswire) - A recent international GfK survey (http://www.gfk.com/global-studies/global-study-overview/), conducted online in 16 countries, shows one in three people (33 percent) currently monitor or track their health or fitness via an online or mobile application, or via a fitness band, clip, or smartwatch. China is well in the lead for ...
mehr
28.09.2016 – 08:33
Merck Healthcare Germany
Merck KGaA, Darmstadt, Germany to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media ESMO Abstract # Avelumab: 777PD, 7775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck KGaA, Darmstadt, Germany, to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell ...
mehr
28.09.2016 – 08:27
Merck Healthcare Germany
Merck to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ESMO Abstract # Avelumab: 777PD, 775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell carcinoma, and ...
mehr
22.09.2016 – 20:12
Merck Healthcare Germany
Merck and the Royal Health Awareness Society Partner to Advance Women's Health in Jordan
Darmstadt, Germany (ots/PRNewswire) - - New partnership under Healthy Women, Healthy Economies initiative facilitates women to overcome health barriers to economic participation Merck, a leading science and technology company, today announced its partnership with the Royal Health Awareness Society (RHAS) of Jordan to advance health awareness and education particularly ...
mehr
16.09.2016 – 12:39
Merck Healthcare Germany
Merck Presents New Data Examining Durable Efficacy with Investigational Cladribine Tablets in Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Phase III studies highlight lasting reductions in relapse rates for an additional two years following short oral treatment courses in year one & year two with Cladribine Tablets Merck, a leading science and technology company, announced they ...
mehr

15.09.2016 – 21:31
Merck Healthcare Germany
Merck Announces 2016 Recipients of EUR1 Million Grant for Multiple Sclerosis Innovation
Darmstadt, Germany (ots/PRNewswire) - - Four research grants awarded out of 260 proposals from 45 countries Merck, a leading science and technology company, today announced recipients of the fourth annual Grant for Multiple Sclerosis Innovation (GMSI) during a symposium at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...
mehr
13.09.2016 – 12:01
Novo Nordisk
Adults with Type 2 Diabetes Treated with Xultophy® (IDegLira) were up to 4.5 Times More Likely to Reach Glycaemic Targets Without Hypoglycaemia and Weight Gain vs Up-titration with Insulin Glargine U100
Munich, Germany (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly ...
mehr
12.09.2016 – 15:09
Merck Healthcare Germany
Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS Congress
Darmstadt, Germany (ots/PRNewswire) - - Two oral presentations and nine posters include new analyses on investigational Cladribine Tablets - Real-world data assess the safety, tolerability and effectiveness of Rebif® - Symposium highlights unmet needs among patients with MS and real-word issues - Grant for Multiple ...
mehr
02.09.2016 – 13:17
GfK SE
Home Improvement: Women Aspire to Better Décor; Men to Better Size and Layout
Nuremberg, Germany (ots/PRNewswire) - - International findings show top five countries most interested in each area of home improvement When it comes to what aspect of their home people would most like to improve, the most popular answers among the online population across 22 countries are the interior décor or design (39 percent), the overall size or layout (38 ...
mehr
28.07.2016 – 08:27
Merck Healthcare Germany
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 - Merck is the first pharmaceutical company to collaborate with multiple diagnostic providers to support liquid biopsy RAS biomarker testing worldwide ...
mehr
21.07.2016 – 10:02
GfK SE
One in Three 'Always Concerned' About Their Safety and Security
Nuremberg, Germany (ots/PRNewswire) - - In Brazil and Turkey that rises to over a half - Sweden, Germany and Netherlands lead for feeling safe - Women not always more safety concerned than men Close to a third (32 percent) of the online population across 21 countries firmly agree[1] they are always concerned about their safety and security, compared to ten percent who firmly indicate[1] that they are not. GfK asked over ...
mehr

18.07.2016 – 08:01
Merck Healthcare Germany
Merck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product Cladribine Tablets for the treatment of relapsing-remitting multiple ...
mehr
01.07.2016 – 10:43
Merck Healthcare Germany
Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST - Phase III study shows response rate of 61.1% for patients treated with Erbitux plus FOLFOX - 31% decrease in risk of disease progression and 24% decrease in risk of ...
mehr
22.06.2016 – 11:02
GfK SE
"Always reachable" Mindset is Above 40 Percent, led by Russia, China and Turkey
Nuremberg, Germany (ots/PRNewswire) - Internationally, 42 percent of the online connected population agree firmly[1] with the statement "To me, it is important to always be reachable wherever I am" - and only 11 percent firmly disagree[1]. However, four countries - Germany, Sweden, Canada and Netherlands - run counter to this trend, with more of their connected ...
mehr
13.06.2016 – 09:03
Merck Healthcare Germany
Merck in Agreement with HAPPYneuron to Offer First-of-its-Kind e-Health Solution for People Living with Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - Agreement provides Merck with exclusive license to cognitive remediation training programs - HAPPYneuron will be available for inclusion in Merck's MSdialog platform for use with Rebif® (interferon beta-1a) Merck, a leading science and technology company, announced today that ...
mehr
04.06.2016 – 15:09
Merck Healthcare Germany
Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - BEACON CRC trial will assess efficacy of combination regime Erbitux® (cetuximab), binimetinib and encorafenib in BRAF-mutant metastatic colorectal cancer (mCRC) Merck, a leading science and technology company, jointly announced with ...
mehr
25.05.2016 – 08:46
Merck Healthcare Germany
Merck to Present Data on Rebif® (interferon beta-1a) and Cladribine Tablets for Multiple Sclerosis at 2nd Congress of the European Academy of Neurology
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that clinical data on Rebif® (interferon beta-1a), the company's high-dose, high-frequency interferon beta for relapsing forms of multiple sclerosis, and Cladribine Tablets, an investigational, oral, small ...
mehr

24.05.2016 – 10:05
GfK SE
Pet-owners Dominate in Latin America, Russia and USA
Nuremberg, Germany (ots/PRNewswire) - - Over half of people internationally have at least one pet - Argentina, Mexico and Brazil have highest percentage of pet-owners, followed by Russia and USA - Asians are least likely to own a pet Over half (56 percent) of people internationally have at least one pet living with them, with dogs proving most popular in Latin America, while Russian and French pet-owners prefer cats. This ...
mehr
18.05.2016 – 23:16
Merck Healthcare Germany
Bringing Innovation to Patients: Merck Presents New Advances at ASCO 2016
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # Avelumab: 4009, TPS4134, TPS4135, 9036, TPS9105, 3055, TPS3106, 8503, 4514, 4516, 5533, TPS5600, TPS4580, 9508; tepotinib: 4072 - Abstracts featuring Merck compounds span a broad range of cancers, with an emphasis on those which are difficult-to-treat and represent ...
mehr
10.05.2016 – 10:01
GfK SE
Hong Kong, North America and UAE Are World's Most "Connected" Populations
Nuremberg, Germany (ots/PRNewswire) - Hong Kong and North America have the world's most highly connected consumers - but people in the United Arab Emirates are closing in fast. The new GfK Connected Consumer Index (http://connected-consumer.gfk.com/connected-consumer-index/) is a ranking of 78 countries and eight world regions that provides fast and direct comparison ...
mehr
05.05.2016 – 11:01
GfK SE
Channel Collision: Drivers of Online and In-store Shopping Are Not as Sharply Divided as you Think
Nuremberg, Germany (ots/PRNewswire) - Traditionally, the primary drivers for online shopping are seen as being consumers' desire for better price, time saving and choice, in particular access to the 'long tail'. In-store shopping, on the other hand, is seen as driven by the better experience delivered face to face ...
mehr
28.04.2016 – 11:02
GfK SE
Savers Just Outnumber Fun-lovers, Internationally
Nuremberg, Germany (ots/PRNewswire) - Internationally, people with a 'save now' mindset just outnumber people with a 'have fun now' mindset. GfK asked 27,000 internet users across 22 countries to say how strongly they agree or disagree with the statement "I want to enjoy life today and will worry about savings and investments later". Internationally, a third (34 percent) of online consumers say they agree - made up of 12 ...
mehr
25.04.2016 – 08:13
Merck Healthcare Germany
Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Chinese pivotal Phase III study meets its primary endpoint of increased progression-free survival in first-line treatment of patients with RAS wild-type metastatic colorectal cancer - Merck will work with relevant authorities to make ...
mehr

Vorherige45678910111213Nächste